Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics

Leukemia

Volumn 27, Issue 9, 2013, Pages 1940-1943

  Grossmann, V ^a   Bacher, U ^a   Haferlach, C ^a   Schnittger, S ^a   Potzinger F ^a   Weissmann, S ^a   Roller, A ^a   Eder, C ^a   Fasan, A ^a   Zenger, M ^a   Staller, M ^a   Kern, W ^a   Kohlmann, A ^a   Haferlach, T ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE ERYTHROID LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; HUMAN; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENETIC MARKERS; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; YOUNG ADULT;

EID: 84883742363     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.144     Document Type: Letter

References (15)

1. Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR. Erythroleukaemia in the north of England: a population based study. J Clin Pathol 2001; 54: 608-612. (Pubitemid 32756442)
2. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood 2010; 115: 1985-1992.
3. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S et al. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 2009; 23: 2275-2280.
4. Bacher U, Haferlach C, Alpermann T, Kern W, Schnittger S, Haferlach T. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Haematologica 2011; 96: 1284-1292.
5. Zuo Z, Medeiros LJ, Chen Z, Liu D, Bueso-Ramos CE, Luthra R et al. Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. PLoS One 2012; 7: e41485.
6. Arber D, Brunning R, Orazi A, Porwit A, Peterson L, Thiele J et al. Acute myeloid leukemia, not otherwise specified. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. edn. IARC Press: Lyon, 2008, pp 130-139.
7. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21: 4496-4504. (Pubitemid 46603514)
8. Kohlmann A, Klein HU, Weissmann S, Bresolin S, Chaplin T, Cuppens H et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011; 25: 1840-1848.
9. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
10. Walter MJ, Shen D, Shao J, Ding L, White B, Kandoth C et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013; 27: 1275-1282.
11. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120: 2963-2972.
12. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814)
13. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66. (Pubitemid 35177429)
14. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. (Pubitemid 34627197)
15. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119: 2114-2121.